Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05836779 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)
A Phase 2 study of Cellulite, sponsored by Caliway Biopharmaceuticals Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 5
- Study locations
NCT05836779 is a Phase 2 study of Cellulite that has completed, run by Caliway Biopharmaceuticals Co.. The registered enrollment target is 23 participants, below the 168-participant average among 5 other Cellulite trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT05836779, a Phase 2 study of Cellulite, has completed, sponsored by Caliway Biopharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Stage 2 of this phase 2 study is an open-label, single-arm study to assess the efficacy and safety of CBL-514 in participants with Edematous Fibrosclerotic Panniculopathy (EFP) cellulite.
Conditions Studied
Interventions
- DRUG CBL-514 injection
Study Locations (5)
California
- Investigational Site 6 - Encinitas
- Investigational Site 1 - Encino
- Investigational Site 3 - San Diego
Florida
- Investigational Site 4 - Coral Gables
New York
- Investigational Site 2 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-05-10 |
| Est. Completion | 2024-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05836779
The ClinicalTrials.gov registry entry for NCT05836779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 5 other Cellulite trials with a reported enrollment target (86% lower). The listed sponsor is Caliway Biopharmaceuticals Co., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cellulite appearing as the primary indexed condition, and to 1 intervention - of which CBL-514 injection is the first listed.
NCT05836779 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT05836779 about?
NCT05836779 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2)". The Stage 2 of this phase 2 study is an open-label, single-arm study to assess the efficacy and safety of CBL-514 in participants with Edematous Fibrosclerotic Panniculopathy (EFP) cellulite.
What is the current status of trial NCT05836779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2023-05-10. Estimated completion is 2024-01-05.
What conditions does trial NCT05836779 study?
This clinical trial studies the following conditions: Cellulite.
What interventions are being tested in trial NCT05836779?
The interventions under investigation include: CBL-514 injection (DRUG).
Who is sponsoring clinical trial NCT05836779?
This trial is sponsored by Caliway Biopharmaceuticals Co., which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05836779 being conducted?
This trial has 5 study locations across California, Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cellulite
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
COMPLETED · Phase 2
-
Minimally Invasive Active Release of Septa Bands for Cellulite and Connective Tissue Release for Fibrosis Treatment in Body Contouring Surgery
RECRUITING · NA
-
Cyrolipolysis vs Cyrolipolysis and Subcision for Cellulite
ACTIVE NOT RECRUITING · NA
-
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
COMPLETED · Phase 1
-
Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.